| Role of B cells as antigen presenting cells I Rastogi, D Jeon, JE Moseman, A Muralidhar, HK Potluri, DG McNeel Frontiers in immunology 13, 954936, 2022 | 177 | 2022 |
| Generation of knock-out primary and expanded human NK cells using Cas9 ribonucleoproteins MN Kararoudi, H Dolatshad, P Trikha, SRA Hussain, E Elmas, JA Foltz, ... Journal of visualized experiments: JoVE, 58237, 2018 | 71 | 2018 |
| TGFβ imprinting during activation promotes natural killer cell cytokine hypersecretion JA Foltz, JE Moseman, A Thakkar, N Chakravarti, DA Lee Cancers 10 (11), 423, 2018 | 51 | 2018 |
| PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy CD Zahm, JE Moseman, LE Delmastro, D G. Mcneel Oncoimmunology 10 (1), 1912892, 2021 | 40 | 2021 |
| Defining the AHR-regulated transcriptome in NK cells reveals gene expression programs relevant to development and function P Trikha, JE Moseman, A Thakkar, AR Campbell, E Elmas, JA Foltz, ... Blood Advances 5 (22), 4605-4618, 2021 | 23 | 2021 |
| Treatment combinations with DNA vaccines for the treatment of metastatic castration-resistant prostate cancer (mCRPC) M Gamat-Huber, D Jeon, LE Johnson, JE Moseman, A Muralidhar, ... Cancers 12 (10), 2831, 2020 | 22 | 2020 |
| Evaluation of serum-free media formulations in feeder cell–stimulated expansion of natural killer cells JE Moseman, JA Foltz, K Sorathia, EL Heipertz, DA Lee Cytotherapy 22 (6), 322-328, 2020 | 22 | 2020 |
| Role of B cells as antigen presenting cells. Front. Immunol. 13, 954936 I Rastogi, D Jeon, JE Moseman, A Muralidhar, HK Potluri, DG McNeel | 6 | 2022 |
| Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy D Jeon, E Hill, JE Moseman, DG McNeel Journal for Immunotherapy of Cancer 12 (5), 2024 | 4 | 2024 |
| Anti-tumor dna vaccine with pd-1 and lag-3 pathway blockade D McNeel, CD Zahm, J Moseman US Patent App. 18/597,446, 2024 | | 2024 |
| 1028 Toll like receptor agonists can affect the activation of human CD8+ T cells with downregulation of T cell checkpoint receptor expression D Jeon, E Hill, JE Moseman, DG McNeel Journal for ImmunoTherapy of Cancer 12 (Suppl 2), 2024 | | 2024 |
| 1042 A nucleic acid vaccine strategy containing mRNA-LNP plus pDNA leads to marked expansion in CD8 T cells and alterations in T cell phenotype JE Moseman, HM Martin, JA Choe, F Ferraresso, CJ Kastrup, WL Murphy, ... Journal for ImmunoTherapy of Cancer 12 (Suppl 2), 2024 | | 2024 |
| 1141 Immunization with plasmid DNA versus messenger RNA encapsulated in lipid nanoparticles leads to differences in immunological outcomes J Moseman, HM Brinkman, W Murphy, D McNeel Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Overcoming immune suppression with tgf-b resistant nk cells DA Lee, P Trikha, A Thakkar, J Foltz, MN Kararoudi, JE Moseman US Patent App. 17/922,248, 2023 | | 2023 |
| Anti-tumor dna vaccine with pd-1 and lag-3 pathway blockade D McNeel, CD Zahm, J Moseman US Patent App. 17/732,237, 2022 | | 2022 |
| 473 PD-1 blockade administered before or at the time of T cell activation enhances anti-tumor immunity J Moseman, D McNeel Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| Assay for immune cell recovery DA Lee, JE Moseman US Patent App. 17/641,473, 2022 | | 2022 |
| TRANSFORMATION OF NATURAL KILLER CELLS RESISTANT TO BETA GROWTH FACTOR DA LEE, JA FOLTZ-STRINGFELLOW, J EDWARDS-MOSEMAN | | 2021 |
| células exterminadoras naturais beta-resistentes ao fator de crescimento de transformação DA Lee, JA FOLTZ-STRINGFELLOW, J EDWARDS-MOSEMAN | | 2021 |
| Transforming growth factor beta-resistant natural killer cells DA Lee, JA Foltz-stringfellow, J Edwards-moseman US Patent App. 16/966,367, 2020 | | 2020 |